The composition and batch numbers of the vaccines administered in the primary series and booster parts are described elsewhere for Study 1 (DTaP-IPV-HB-PRP~T [Hexaxim; Sanofi Pasteur], DTwP/PRP~T [CombAct-Hib; Sanofi Pasteur], HB [Engerix B; GlaxoSmithKline], OPV [Sanofi Pasteur], MMR [ROR, Sanofi Pasteur], and V [Varilrix, GlaxoSmithKline])16 ,24 and Study 2 (DTaP-IPV-HB-PRP~T [Hexaxim; Sanofi Pasteur], DTaP-IPV-HB//PRP~T [Infanrix hexa; GlaxoSmithKline], PCV7 [Prevenar; Pfizer], and rotavirus [Rotarix; GlaxoSmithKline]).20 The DTaP-IPV-HB-PRP~T, DTaP-IPV-HB//PRP~T, PCV7, and HB vaccines were administered intramuscularly, MMR was administered either intramuscularly or subcutaneously, V was administered subcutaneously, and rotavirus vaccine was administered orally (see Figure 1 for subjects disposition).
Hexaxim
Manufactured by Sanofi
Hexaxim is a laboratory equipment product manufactured by Sanofi. It is designed to perform a specific function in the laboratory setting. The core function of Hexaxim is to provide a controlled and reliable platform for certain laboratory processes, though the precise intended use is not included in this factual description.
Automatically generated - may contain errors
2 protocols using hexaxim
1
Infant Vaccination Protocols and Administration
2
Tenofovir for HBV-Positive Pregnant Women
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
International guidelines, such as the AASLD guidelines, do not recommend treating women with HB viral loads lower than 200 000 IU/ml as their infants will be receiving both HBIG and HBV birth-dose vaccine. However, in the present study, since HBIG was not available for use owing to its high cost, treatment was discussed and offered to participating pregnant women with HB viral loads greater than 20 000 IU/ml. Those who qualified for treatment under these criteria were reviewed at the Hepatology Clinic and offered a 300 mg TDF tablet daily, starting after 28 weeks gestation until one month after delivery. The women were monitored for hepatic flares for one month post-treatment. The risks and benefits of therapy were clearly explained. All HBV-exposed infants received a birth dose of the standard monovalent, yeast-derived HBV vaccine (Heberbiovac HB: 10 μg in 0.5 ml). They were subsequently vaccinated with the hexavalent vaccine (Hexaxim® Sanofi Pasteur: 10 μg of HBsAg in 0.5 ml) at 6 and 10 weeks [5 (link)].
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!